# EDGAR Filing Document

**Accession Number:** 0001575142
**File Stem:** 0001640334-26-000718
**Filing Date:** 2026-4
**Character Count:** 160155
**Document Hash:** 99d2f93b637527dec102818015d4b47c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-26-000718.hdr.sgml**: 20260414

**ACCESSION NUMBER**: 0001640334-26-000718

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 63

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260414

**DATE AS OF CHANGE**: 20260414

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOADAPTIVES, INC.
- **CENTRAL INDEX KEY:** 0001575142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462592228
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-54949
- **FILM NUMBER:** 26860868

**BUSINESS ADDRESS:**
- **STREET 1:** 2620 REGATTA DRIVE
- **STREET 2:** SUITE 102
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89128
- **BUSINESS PHONE:** (702) 659-8829

**MAIL ADDRESS:**
- **STREET 1:** 2620 REGATTA DRIVE
- **STREET 2:** SUITE 102
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** APEX 8 Inc.
- **DATE OF NAME CHANGE:** 20130424

?xml version='1.0' encoding='ASCII'? bdpt_10k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**Form 10-K&nbsp;&nbsp;&nbsp;&nbsp;** 

**(Mark one)**

**☒** **Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934**

**For the fiscal year ended <u>December 31, 2025</u>**

**☐** **Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934** 

**For the transition period from ______________ to _____________**

**Commission File Number: <u>000-54949</u>**

![bdpt_10kimg1.jpg](bdpt_10kimg1.jpg)

---

| |
|:---|
| **BioAdaptives, Inc.** |
| **(Exact name of registrant as specified in its charter)** |

---

---

| | |
|:---|:---|
| **Delaware** | **46-2592228** |
| **(**State of incorporation) | (IRS Employer ID Number) |

---

**<u>2620 Regatta Drive, Suite 102, Las Vegas, NV</u>**

(Address of principal executive offices)

**<u>(702) 659-8829</u>**

(Issuer's telephone number)

**__________________________________________________________________________________________** 

Securities registered pursuant to Section 12 (b) of the Act - None

Securities registered pursuant to Section 12(g) of the Act: - Common Stock - $0.0001 par value

**__________________________________________________________________________________________** 

**Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒**

**Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒**

**Indicate by check mark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the**

**Exchange Act during the past 12 months (or for such shorter period the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐**

**Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post files). Yes ☒ No ☐**

**Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐**

**Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):**

---

| | | | |
|:---|:---|:---|:---|
| **Large accelerated filer** | **☐** | **Accelerated filer** | **☐** |
| **Non-accelerated filer** | **☐** | **Smaller reporting company** | **☒** |

---

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒**

**The aggregate market value of voting and non-voting common equity held by non-affiliates as of December 31, 2025 was approximately $252,181.80 based upon 12,008,659 shares issued and outstanding.**

**As of December 31, 2025, there were 12,008,65 shares of Common Stock issued and outstanding. As of March 24, 2025, we had 12,008,659 shares of our Common Stock issued and outstanding.**

**BioAdaptives, Inc.**

**Form 10-K for the Year Ended December 31, 2025**

**BioAdaptives, Inc.**

**Form 10-K for the Year Ended December 31, 2025**

**Index to Contents**

---

| | | |
|:---|:---|:---|
| **[Part I](#p1)** |  | **Page Number** |
| [Item 1](#i1) | [Business](#i1) | 4 |
| [Item 1A](#i1a) | [Risk Factors](#i1a) | 7 |
| [Item 1B](#i1b) | [Unresolved Staff Comments](#i1b) | 12 |
| [Item 2](#i2) | [Properties](#i2) | 12 |
| [Item 3](#i3) | [Legal Proceedings](#i3) | 12 |
| [Item 4](#i4) | [Mine Safety Disclosures](#i4) | 12 |
| **[Part II](#p2)** |  |  |
| [Item 5](#i5) | [Market for Registrant's Common Equity, Related Stockholder Matters and](#i5) | 13 |
| [Item 6](#i6) | [Selected Financial Data](#i6) | 15 |
| [Item 7](#i7) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#i7) | 15 |
| [Item 7A](#i7a) | [Quantitative and Qualitative Disclosures About Market Risk](#i7a) | 18 |
| [Item 8](#t8) | [Financial Statements, Auditor's Notes and Supplemental Data](#t8) | 18 |
| Item 9 | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Controls and Procedures |  |
| Item 9B | Other Information |  |
| **[Part III](#p3)** |  |  |
| [Item 10](#i10) | [Directors, Executive Officers and Corporate Governance](#i10) | 19 |
| [Item 11](#i11) | [Executive Compensation](#i11) | 22 |
| [Item 12](#i12) | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i12) | 23 |
| [Item 13](#i13) | [Certain Relationships and Related Transactions, and Director Independence](#i13) | 24 |
| [Item 14](#i14) | [Principal Accountant Fees and Services](#i14) | 25 |
| **Part IV** |  |  |
| [Item 15](#i15) | [Exhibits, Financial Statement Schedules](#i15) | 25 |
| [Item 16](#i16) | [Form 10-K Summary](#i16) | 25 |
| **Signatures** | **Signatures** |  |

---

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#TOC)* |

---

Caution Regarding Forward-Looking Information

Certain statements contained in this annual filing, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

Where You Can Find Information

The public may read and copy any materials we file with the SEC in the SEC's Public Reference Section, Room 1580,100 F Street N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Section by calling the SEC at 1-800-SEC-0330. Additionally, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, which can be found at www.sec.gov or <u>www.freeedgar.com.</u>

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#TOC)* |

---

**PART I**

**Item 1 - Business**

**The Company's History**

BioAdaptives, Inc., ("BioAdaptives," the "Company," "we" or "us") was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the "Registration Statement"), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments.

On January 10, 2014, the SEC notified the Company that the registration statement was effective and on July 9, 2014, the Company's shares commenced trading in the Over-the-Counter market under the trading symbol BDPT.

On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market and it also continued to execute its business plan.

On May 10, 2019, the Company filed a Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing.

On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained as Chief Executive Officer.

On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. The Series A has enhanced voting and conversion privileges and can be used by the Company to settle recorded debt or exchange for new product rights or techniques. On this same day, the Board of Directors authorized an increase in the Company's authorized common stock from 100,000,000 to 200,000,000; holders of a majority of **t**he Company's common shares consented to the increase.

On January 26, 2022, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. The Series B has enhanced voting and conversion privileges and can be used by the Company to acquire ownership of intellectual property rights and other assets. On this same day, the Board of Directors authorized an increase in the Company's authorized common stock from 200,000,000 to 750,000,000; this increase received the consent of the holders of a majority of the Company's common shares. consented to the increase

On March 18, 2022, the Company filed a Form 1-A with the Securities and Exchange Commission covering a plan to sell up to 200,000,000 shares of common stock for prices between .005 and .01 per share. This was amended on October 7 2022 to 250,000,000 shares of common stock at the price of 0.001.

On February 28 2023, the Board of Directors exercised its authority under the Delaware General Corporation Law to increase the Company's authorized common stock from 750,000,000 to 1,250,000,000; this holders of a majority of the Company's shares consented to the increase.

On May 15 2024, Dr. Edward Jacobs retired from the Company and was succeeded by Mr James E Kneer as Chairman and CEO. Mr. Gimhana Dissanayake joined him as a Director of the Company as of May 27, 2024.

On October 28, 2024, the Board unanimously resolved move forward with a reverse split of 1 for 300 shares. On December 3, 2024 the Board of Directors Approved a One-for-One Stock Dividend to holders of common stock.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#TOC)* |

---

**The Company's Business**

**Overview**

BioAdaptives' core business is to investigate, market, and distribute natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. BioAdaptives is reformulating its entire product line and started bringing out new products from the second quarter of 2025.

Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung Flute™. In April 2024, The Company negotiated with the sole owner of the product to assume their existing stock and their rights to all future activities on this item. It intends to actively expand its sales efforts beyond the direct sales effort of its Lung Cleanser to target medical communities, pharmacies, gyms, athletic clubs, and senior communities, both in the US and internationally. The Company is also exploring agreements with other medical device manufacturers, the owners of intellectual property related to medical devices and processes, as well as marketing companies associated with these manufacturers and owners.

The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. MyndMed™ provides Immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Zeranovia™ is a healthy weight loss enhancer, and Wynovia™ is used to help reduce the loss of lean muscle mass during dieting.

Beginning in April, the Company completed preparations to launch the Canine Product – PawPa®Regen. Backed by science and advanced technology, PawPa®'s products not only enhance pet wellness but also set the new standard in pet care. "Regen" dog chew PawPa®'s flagship product is crafted with a blend of advanced nutraceutical compounds and infused with all-natural ingredients; these chews are specially formulated to enhance canines' quality of life in their golden years. Specific benefits of the "Regen" chew include Regenerative Support, Energy & Vitality, and Anti-aging Benefits.

The Company's Product MyndMed™ is completing its pre-launch phase. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health.

It aids in a rapid increase in motivation, sustained attention, and mental clarity, and helps in tackling demanding cognitive tasks with greater drive and efficiency. The product underwent rigorous testing by TruShield and received its TruShield Certified Certification, which provides the brand with a trusted, science-backed way to demonstrate that the product is free from banned substances.

Xcellara™ is BioAdaptives' regenerative wellness solution to enhance your performance, accelerate recovery, and revitalize your health. Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds, Xcellara™ is the secret weapon for success on and off the court, providing a myriad of benefits. In its market testing, Xcellera™ has demonstrated a positive effect on individuals challenged by chronic fatigue.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#TOC)* |

---

Zeranovia™ has been going through a further refining process. It is about to complete its clinical trial for launching in the last quarter. Zeranovia™ is an innovative, natural weight loss supplement designed to work exceptionally well on its own or as a complement to GLP-1 and GIP weight loss treatments such as Ozempic, Wegovy, Zepbound, and Mounjaro. It supports weight loss by dramatically suppressing appetite, enhancing insulin sensitivity, preserving muscle mass, and delivering essential nutrients. Zeranovia™ significantly improves the effectiveness of existing treatments while providing substantial nutritional support to prevent muscle wasting during a caloric deficit. Throughout the trial, extremely encouraging results have been reported of participants losing 5 to 11 pounds in a 7 to 10 day period.

**Market and Marketing**

BioAdaptives Inc. has developed a robust direct-to-consumer (DTC) digital marketing campaign to connect directly with its target audience. Leveraging platforms like social media, email marketing, and a user-friendly website, the company promotes its supplement products with engaging content tailored to health-conscious consumers. Through targeted ads, informative blog posts, and compelling calls to action, BioAdaptives ensures its messaging resonates, driving awareness and conversions while fostering a community around wellness and natural health solutions.

In addition to its DTC efforts, BioAdaptives has forged strategic partnerships within the telehealth industry to enhance its product offerings. By aligning its supplements as both companion products and standalone solutions, the company integrates seamlessly with telehealth platforms, providing participants with accessible, science-backed options to support their wellness journeys. These collaborations not only expand BioAdaptives' reach but also position our products as trusted recommendations within virtual healthcare ecosystems, capitalizing on the growing demand for telehealth services.

Finally, BioAdaptives employs a dynamic affiliate marketing program, partnering with companies and individual influencers who boast large social media followings and a proven track record of success in the supplement industry. These affiliates, carefully selected for their credibility and performance, promote BioAdaptives' products through authentic endorsements, affiliate links, and promo codes. This strategy amplifies brand visibility, drives sales, and builds trust among niche audiences, leveraging the influence of established voices in the health and wellness space to accelerate growth.

**Manufacturing**

All of the Company's nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug, or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant, fungi, algal, or cyanobacteria-based and sourced worldwide from reputable suppliers that employ stringent compliance and sustainable agricultural practices.

BioAdaptives actively investigates new products, techniques, and novel applications of existing products or technology in our research. The Company's research has focused on investigating all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, as well as natural ingredients that promote stem cell proliferation. In 2022, the Company started a product line utilizing cyanobacteria and mushrooms.

With regard to medical devices, in April 2024, we purchased the Lungflute™ from the sole US affiliate of the patent holder. We do not expect to develop any direct capability to manufacture medical devices for several reasons, including a lack of capital and the fact that the amortized cost of such facilities, if we were to construct or acquire them, is generally far higher than the cost of purchasing a finished product. We operate as a Research and Development nutraceutical company.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#TOC)* |

---

**Employees**

Currently, the Company has one full-time executive employee. We retain hourly labor as needed and professional consultants to manage our business operations. The company's management anticipates utilizing outside consultants, attorneys, and accountants as needed. The need for additional employees and their availability will be taken into account when deciding whether to acquire or participate in specific business opportunities.

**Item 1A - Risk Factors**

We have a limited operating history with our current business. The Company was incorporated in 2013 and was unsuccessful at previous business plans.

The Company has been engaged in the health and wellness industry since the FHI and BioSwan acquisitions in 2013. We have the benefit of their experience in developing and marketing nutraceutical products but understand that neither of them had significant success exploiting the products and technology we purchased. Future operations are subject to all the problems, expenses, difficulties, complications and delays encountered in establishing new businesses. The Company believes that it will become commercially viable, generate significant revenues, and operate at a profit in future periods but there are no assurances that we will meet these expectations.

The Company has no cash flows to support operations and relies on external sources to maintain the corporate entity.

Our revenues from product sales in the past have not been sufficient to cover our operating expenses, including the expenses associated with our status as a public company, or our research and marketing expenses. We have been reliant on outside financing sources, some of which are dependent on our status as a public company. All of these external sources are subject to general economic and market risks as well as regulatory factors that make future financing uncertain.

The Company will require additional financing to become commercially viable.

The Company's continued existence is dependent on its ability to implement its business plan, generate sufficient cash flows from operations to support its daily operations, and provide sufficient resources to retire existing liabilities and obligations on a timely basis. The Company faces considerable risks in its business plan and a potential shortfall of funding due to uncertainty in our ability to raise adequate capital in the equity securities market.

During the period ended December 31, 2024, there is no sales revenues to cover our expenses so that we were reliant on investment funding to continue operations. Our new products are very good and for a variety of reasons, including because we outsource our manufacturing, we are sufficiently nimble to increase production and sales if and when demand requires. However, these products are still in development stage and will not be on market till first or second quarter of 2025.

In the event that working capital sufficient to maintain the corporate entity and implement our business plan is not available, the Company's existing stockholders have expressed their interest in the possibility of maintaining the corporate status of the Company and provide all necessary working capital on the Company's behalf. However, no formal commitments or arrangements to advance or loan funds to the Company or repay any such advances or loans exist. There is no legal obligation for either management or existing controlling stockholders to provide additional future funding. Further, the Company is subject to future economic trends and the business operations for the Company's existing controlling stockholders in order to have the resources available to support the Company.

The Company anticipates offering future sales of equity securities. However, there is no assurance that the Company will be able to obtain additional funding through the sales of additional equity securities or, that such funding, if available, will be obtained on terms favorable to or affordable by the Company.

In the past, a significant portion of our cash needs have been met through issuance of convertible debt securities. The notes generally carry Original Issue Discounts, provide for cash repayments during the first six (6) months after issuance (with a pre-payment penalty), and allow the holder to demand repayment by issuance of shares of common stock at a discount to market price. In function, these convertible notes act as private placements of our securities, with a variable subscription price based on market performance. On those terms, as subscription rather than debt, the rates and conversion amounts have so far been reasonable to us. Moreover, our agreements with these lenders contain representations that 1) there was no public solicitation for the notes, 2) that the note holders are "accredited" investors within the meaning of SEC Regulation D, and 3) that the holders will limit their conversions in a manner to assure they never hold more than 4.99% of the Company's issued and outstanding shares. We have no assurances that we will be able to continue to borrow funds from these lenders and have been working to develop alternative financing means through more traditional methods.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#TOC)* |

---

Since May 2024, the Company has welcome new investment partners in acquiring its preferred D shares. Should future needs arise, the Company intends to raise funds in the equity securities market. The Company believes that its expectations as to its ability to secure additional capital are reasonable, but there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.

The Company's current business can be capital intensive.

The Company acknowledges that its Plan of Operations may not result in the consistent generation of positive working capital in the near future. We are in a consumer-driven market space that requires our development and marketing of attractive products, which is expensive. Although management believes that it will be able to successfully execute its business plan, which includes third party financing and the raising of capital to meet the Company's future liquidity needs, there can be no assurances. We anticipate continuous expenditures, some of which may be significant, to conduct research and development activities relating to existing and new products and marketing. These matters raise substantial doubt about the Company's ability to continue as a going concern

We currently rely on certain key individuals, and the loss of one of these key individuals could have an adverse effect on the Company.

Our success depends to a certain degree upon certain key members of our management. These individuals are a significant factor in our growth and success. The loss of the services of such members of management could have a material adverse effect on our Company. We presently maintain no key-man insurance coverage on any of our officers.

The Company's success will be dependent in part upon its ability to attract qualified personnel and consultants.

The Company's success will be dependent in part upon its ability to attract qualified creative marketing, sales and development professionals. The inability to do so on favorable terms may harm the Company's proposed business.

The Company must effectively meet the challenges of managing expanding operations.

The Company's business plan anticipates that operations will undergo significant expansion during 2024 and beyond. This expansion will require the Company to manage a larger and more complex organization, which could place a significant strain on our managerial, operational and financial resources. Management may not succeed with these efforts. Failure to expand in an efficient manner could cause expenses to be greater than anticipated, revenues to grow more slowly than expected and could otherwise have an adverse effect on the business, financial condition and results of operations.

Our business could be affected by changes in governmental regulation.

Federal, State and Local laws and regulations governing food products and nutritional supplements are broad in scope and are subject to evolving interpretations, which could require us to incur substantial costs associated with compliance. In addition, violations of these laws, actual or alleged, could disrupt the Company's planned business and adversely affect our financial condition and results of operations. In addition, it is possible that additional or revised Federal, State and Local laws and regulations may be enacted in the future governing the mining industry. There can be no assurance that the Company will be able to comply with any such laws and regulations and its failure to do so could significantly harm our business, financial condition and results of operations.

Our business will be subject to other, uninsured operating risks which may adversely affect the Company's financial condition.

Our planned operations will be subject to risks normally incidental to our business activities and will be dependent on internal and third-party production and distribution operations that could result in work stoppages, damage to property or unavailable product for resale. This may be caused by:

Breakdown of equipment.

Labor disputes.

Imposition of new government regulations.

Supply chain failures.

Product contamination.

Unanticipated allergic or other reactions.

Sabotage by operational personnel.

Cost overruns; and

Fire, flood, or other acts of God.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#TOC)* |

---

We market products that are ingested by our customers and run additional risks incumbent to sales of this manner of consumer good. Our existing insurance coverage would almost certainly be inadequate to deal with any manner of mass tort claim and the ability of our suppliers to indemnify us is uncertain. Additionally, our contract suppliers are reliant on source materials that are imported from China and other countries, so that we are subject to risks associated with interruptions or pricing increases due to political and other reasons.

We will likely face significant competition.

The nutraceutical industry is highly competitive, with numerous companies offering products that claim similar properties to ours. Some of these competitors are better capitalized, with the financial ability to effectively manage product development and marketing at levels we have not yet attained. While we believe our whole plant- and algal-mushroom based products have unique benefits that should lead to commercial success, BioAdaptive's ability to effectively compete could be hindered by a lack of funds, poor positioning, management error, and other factors. The inability to effectively compete could adversely affect our business, financial condition and results of operations.

**RISKS RELATED TO OUR PUBLIC COMPANY STATUS AND OUR COMMON STOCK**

Our internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

We do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies that we may not be able to timely remediate. In addition, if we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 ("Sarbanes Oxley"). Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading

The costs of being a public company could result in us being unable to continue as a going concern.

As a public company, we are required to comply with numerous financial reporting and legal requirements, including those pertaining to audits and internal control. The costs of this compliance could be significant. If our revenues do not increase and/or we cannot satisfy many of these costs through the issuance of our shares, we may be unable to satisfy these costs in the normal course of business that would result in our being unable to continue as a going concern.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#TOC)* |

---

Management and the Board of Directors may be Indemnified.

The Articles of Incorporation and Bylaws of BioAdaptives provide for indemnification of directors and officers at the expense of the respective corporation and limit their liability. This may result in a major cost to the corporation and hurt the interests of stockholders because corporate resources may be expended for the benefit of directors and officers. The Company has been advised that, in the opinion of the SEC, indemnification for liabilities arising under Federal Securities Laws is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

The market for the BioAdaptives Shares is extremely limited and sporadic.

BioAdaptives' common stock is quoted on the OTC Pink Sheets; trading is limited and sporadic. Trading in stock quoted on the Pink Sheets is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. This volatility could depress or exaggerate the market price of BioAdaptives' common stock for reasons unrelated to operating performance. Moreover, the trading of securities in the Pink Sheets is often more sporadic than the trading of securities listed on a quotation system like NASDAQ, or a stock exchange like the New York Stock Exchange. These factors may impact on our ability to obtain financing in the future and will certainly have an impact on the value of our common stock for shareholders.

BioAdaptives' common stock is a penny stock, which is restricted by the SEC's penny stock regulations and FINRA's sales practice requirements, which may limit a stockholder's ability to buy and sell our common stock.

BioAdaptives' common stock is a penny stock. The SEC has adopted Rule 15g-9 which generally defines "penny stock" to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Our common stock is covered by these rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and accredited investors. The term "accredited investor" refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson compensation information must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in, and limit the marketability of, BioAdaptives' common stock.

In addition to the penny stock rules promulgated by the SEC, FINRA (the Financial Industry Regulatory Authority) has adopted rules that require when recommending an investment to a customer a broker- dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low -priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, the FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA's requirements make it more difficult for broker-dealers to recommend that their customers buy BioAdaptives' common stock, which may limit investor ability to buy and sell our common stock.

The market for penny stocks has experienced numerous frauds and abuses that could adversely impact BioAdaptives' common stock.

Company management believes that the market for penny stocks has suffered from patterns of fraud and abuse. Such patterns include:

control of the market for the security by one or a few broker-dealers that are often related to a promoter or issuer.

manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases.

boiler room practices involving high pressure sales tactics and unrealistic price projections by salespersons.

excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and

wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#TOC)* |

---

BioAdaptives' Board of Directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders and with the ability to adversely affect common stockholder voting power and rights upon liquidation.

Our Certificate of Incorporation allows us to issue shares of preferred stock without any vote or further action by our stockholders. Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders of preferred stock the rights to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock. We have done so recently, by establishing the Series A Preferred Stock. We established the Series A Preferred Stock in 2020 and subsequently established the Series B and C Preferred Stock; these preferred shares provide enhanced voting and conversion privileges to holders. These privileges may impact the rights and privileges of common stockholders in certain circumstances. A series D Preferred Stock was approved by the Board in the last quarter of 2024 as well.

We do not expect to pay cash dividends in the foreseeable future.

The Company has never paid cash dividends on its common stock and does not expect to pay a cash dividend on its common stock at any time in the foreseeable future. The future payment of dividends depends upon future earnings, capital requirements, financial requirements and other factors that the Company's board of directors will consider. Since we do not anticipate paying cash dividends on the common stock, return on investment, if any, will depend solely on an increase, if any, in the market value of the common stock.

Future sales of shares of BioAdaptives common stock pursuant to Reg. A+ and Rule 144 under the Securities Act could adversely affect the market price of BIOADAPTIVES's common stock.

As of March 24, 2026, the Company has 12,008,659 outstanding shares of its common stock, all of which were issued pursuant to registration statements and/or exemptions from registration under the Securities Act and applicable State Securities Laws. As of the date of this filing, 7,006,478 common stock are on deposit with CEDE & Co. and are publicly trading or tradeable, and nearly all of the balance is held by purchasers or service providers who obtained shares more than one year ago. All of these "aged" issued and outstanding shares are all now available for public sale pursuant to Rule 144 under the Securities Act and comparable exemptions under applicable state securities laws. The potential of such sales could adversely affect the market price of BioAdaptives' common stock. The impact of these sales on the market cannot be reasonably estimated but absent significant positive news regarding our activities shareholders should expect an adverse impact on market price

Conversions of Series A -B-C-D Preferred Stock to common stock and resales could adversely affect the market price of BIOADAPTIVES' common stock. Preferred stock ownership provides additional voting rights that may affect management.

The Company has 1.219,049 shares of its Series A-B-C-D Preferred Stock issued and outstanding as of the date of this filing. These shares have enhanced voting and conversion privileges so that the owners can either convert to common shares, which could impact market price, or hold and vote the shares under circumstances set out in the Certificate of Designation, allowing them an increased authority over certain corporate functions.

Because we are not subject to compliance with rules requiring the adoption of certain corporate governance measures, our stockholders have limited protection against interested-director transactions, conflicts of interest and similar matters.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#TOC)* |

---

The Sarbanes-Oxley Act of 2002 as well as rule changes proposed and enacted by the SEC, national securities exchanges and the NASDAQ Stock Market as a result of Sarbanes-Oxley, require the implementation of various measures relating to corporate governance. These measures are designed to enhance the integrity of corporate management and the securities markets and apply to securities that are listed on those exchanges or the NASDAQ Stock Market. Because we are not currently required to comply with many of the corporate governance provisions and because we chose to avoid incurring the substantial additional costs associated with voluntary compliance, we have not yet adopted these measures.

We do not currently have independent audit or compensation committees. As a result, directors have the ability, among other things, to determine their own level of compensation. Until we comply with such corporate governance measures, regardless of whether such compliance is required, the absence of such standards of corporate governance may leave our stockholders without protections against interested- director transactions, conflicts of interest and similar matters and investors may be reluctant to provide us with funds necessary to expand our operations as a result thereof.

We intend to comply with all corporate governance measures relating to director independence as and when required. However, we may find it very difficult or be unable to attract and retain qualified officers, directors and members of board committees required to provide for our effective management as a result of Sarbanes-Oxley. The enactment of Sarbanes-Oxley has resulted in a series of rules and regulations by the SEC that increase responsibilities and liabilities of directors and executive officers. The perceived increased personal risk associated with these recent changes may make it more costly or deter qualified individuals from accepting these roles.

**Item 1B - Unresolved Staff Comments**

None

**Item 2 – Properties**

The Company currently maintains a physical address at 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128. The Company does not currently maintain any other office facilities and does not anticipate the need to maintain office facilities at any time in the foreseeable future.

**Item 3 - Legal Proceedings**

The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.

**Item 4 - Mine Safety Disclosures**

Not applicable.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#TOC)* |

---

**PART II**

**Item 5 - Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**

**Market for Trading and Eligibility for Future Sale**

Our common stock started trading on June 10, 2014. Our current trading symbol is "BDPT". Currently there is only a limited, sporadic, and volatile market for our stock. The following table sets forth the high and low sales prices of our common stock as reported on www.nasdaq.com for the periods indicated. These prices represent prices between inter-dealer prices, do not include retail markups, markdowns, or commissions, and do not necessarily reflect actual transactions.

---

| | | |
|:---|:---|:---|
|  | High | Low |
| Fiscal year ended December 31, 2025 | 0.029 | 0.022 |
| Quarter ended December 31, 2025 | 0.029 | 0.022 |
| Quarter ended September 30, 2025 | 0.035 | 0.0249 |
| Quarter ended June 30, 2025 | 0.0699 | 0.0599 |
| Quarter ended March 31, 2025 | 0.0999 | 0.0713 |
| Fiscal year ended December 31, 2024 | 0.0650 | 0.0450 |
| Fiscal year ended December 31, 2023 | 0.0750 | 0.0600 |

---

**T**he closing price of our common stock on March 24, 2026, was $0. 013225 as reported by the OTCQB Bulletin Board.

**Holders of Record**

As of March 21, 2024, we had 12,008,659 shares of our common stock issued and outstanding held by approximately 151 stockholders of record, exclusive of shares held in street name. We had 11,047 shares of Series A preferred stock, 9,667 shares of Series B preferred stock, 1,000,000 shares of Series C preferred stock and 198,335 shares of Series D preferred stock issued and outstanding.

**Transfer Agent**

Our stock transfer agent is Madison Stock Transfer LLC. Their address is 2206 Quentin Road, Brooklyn, NY 11229. Madison is registered by the Securities and Exchange Commission as a transfer agent and is wholly independent of us, with no common ownership or management.

**Common Stock**

The Company is authorized to issue up to 1,250,000,000 shares of common stock with a par value of $0.0001 per share.

Our Board of Directors is authorized to issue additional shares of common stock not to exceed the amount authorized by the Articles of Incorporation, on such terms and conditions and for such consideration as the Board may deem appropriate without further stockholder action.

In the event of our liquidation or dissolution, all shares of our common stock are entitled to share equally in our assets available for distribution to stockholders. However, the rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of preferred stock that our Board of Directors may decide to issue in the future.

**Preferred Stock**

Effective March 13, 2025, the Company is authorized to issue up to 31,000,000 shares of preferred stock with a par value of $0.0001 per share.

As of March 21, 2025, the Company has authorized 4,000,000 shares of Series A Preferred Stock, of which 11,047 shares are issued and outstanding, it has authorized 5,000,000 shares of Series B Preferred Stock, of which 9667 issued or outstanding. As well as 1,000,000 Series C Preferred Stock of which 1,000,000 issued and outstanding, and also 21,000,000 Series D Preferred Stock of which 198,335 are issued and outstanding.

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#TOC)* |

---

**Dividend Policy**

We have never declared or paid cash dividends. We currently intend to retain all future earnings for the operation and expansion of our business and do not anticipate paying cash dividends on the common stock in the foreseeable future. Any payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our results of operations, earnings, capital requirements, contractual restrictions and other factors deemed relevant by our directors. However, to show appreciation to our investing public, the Company did disburse a one-for-one common shares dividend in January 2025.

**Share Purchase Warrants**

We have not issued and do not have outstanding any warrants to purchase shares of our stock.

**Options**

On April 16, 2025, the Company granted stock option of 500,000 shares of common stock to our director for compensation, valued at $28,670 with term of ten years, exercise price of $10.00 per share, fully vested on grant date. During the year ended December 31, 2025, the Company recognized stock option expense of $28,670.

**Warrants**

On November 25, 2025 and November 26, 2025, the Company granted warrants for Jefferson Street Capital, LLC, and Lambda Venture Partners, LLC, 1.031.250 warrants at $0.08 valid for 3 years from dates states.

**Convertible Securities**

The Company has no convertible securities in 2025&nbsp;&nbsp;&nbsp;&nbsp;

**Securities Authorized for Issuance Under Equity Compensation Plans**

The Company and the Chief Executive Officer agreed to an annual compensation of $300,000 payable $25,000 monthly. This may be taken in common or Preferred Stock. As of December 31, 2025, 68,559 amount of Series D shares were allocated to Mr. James Keener, CEO in 2025

Per the Company's Directors' agreement during the term of this Agreement, the Company is to pay a Director, if the Company does not otherwise compensate the Director as an officer or employee, common stock in BDPT based upon the floating average of the close of the five trading days prior to the end of the month preceding the issuance. Such Issuance are to be made within 10 days of the date 0,earned. Shares to be fully earned and paid for on the day of issuance. Payments to be made according to the following schedule: January 1, 2025 to December 31, 2024 $5,000.00 monthly. Total of 13,102 Preferred D stock were allocated for issuance between January 1 2025 to December 31, 2025 to Mr Gimhana Dissanayake.. Payments to be made according to the following schedule: February 15, 2025 to December 31, 2025 $5,000.00 monthly. Total of 12,153 Preferred D stock were allocated for issuance between February 15 to December 31 2025 to Mr. Mark Frissora.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#TOC)* |

---

**Item 6 - Selected Financial Data**

Not applicable

**Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations**

(1) Caution Regarding Forward-Looking Information Certain statements contained in this annual filing, including, without limitation, statements containing the words "believes", "anticipates", "expects" and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

**(2) General**

BioAdaptives, Inc., ("BioAdaptives," the "Company," "we" or "us") was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the "Registration Statement"), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments.

On January 10, 2014, the SEC notified the Company that the registration statement was effective and on July 9, 2014, the Company's shares commenced trading in the Over-the-Counter market under the trading symbol BDPT.

On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market and it also continued to execute its business plan.

On May 10, 2019, the Company filed a Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing.

On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained as Chief Executive Officer.

On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. The Series A has enhanced voting and conversion privileges and can be used by the Company to settle recorded debt or exchange for new product rights or techniques. On this same day, the Board of Directors authorized an increase in the Company's authorized common stock from 100,000,000 to 200,000,000; holders of a majority of the Company's common shares consented to the increase.

On January 26, 2022, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. The Series B has enhanced voting and conversion privileges and can be used by the Company to acquire ownership of intellectual property rights and other assets. On this same day, the Board of Directors authorized an increase in the Company's authorized common stock from 200,000,000 to 750,000,000; this increase received the consent of the holders of a majority of the Company's common shares. consented to the increase

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#TOC)* |

---

On March 18, 2022, the Company filed a Form 1-A with the Securities and Exchange Commission covering a plan to sell up to 200,000,000 shares of common stock for prices between .005 and .01 per share. This was amended on October 7 2022 to 250,000,000 shares of common stock at the price of 0.001.

On February 28 2023, the Board of Directors exercised its authority under the Delaware General Corporation Law to increase the Company's authorized common stock from 750,000,000 to 1,250,000,000; this holders of a majority of the Company's shares consented to the increase.

On May 15 2024, Dr. Edward Jacobs retired from the Company and was succeeded by Mr James E Kneer as Chairman and CEO. Mr. Gimhana Dissanayake joined him as a Director of the Company as of May 27, 2024.

On October 28, 2024, the Board unanimously resolved move forward with a reverse split of 1 for 300 shares. On December 3, 2024 the Board of Directors Approved a One-for-One Stock Dividend to holders of common stock.

**The Company's Business**

**Overview**

BioAdaptives' core business is to investigate, market, and distribute natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. BioAdaptives is reformulating its entire product line and started bringing out new products from the second quarter of 2025.

Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung Flute™. In April 2024, The Company negotiated with the sole owner of the product to assume their existing stock and their rights to all future activities on this item. It intends to actively expand its sales efforts beyond the direct sales effort of its Lung Cleanser to target medical communities, pharmacies, gyms, athletic clubs, and senior communities, both in the US and internationally. The Company is also exploring agreements with other medical device manufacturers, the owners of intellectual property related to medical devices and processes, as well as marketing companies associated with these manufacturers and owners.

The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. The human products are designed to aid in cognitive health, regenerative stem cell activation, and healthy weight loss. MyndMed™ provides Immediate cognitive enhancement (focus, clarity, motivation), medium-term resilience and memory gains, and long-term neuroprotection and cognitive health, making it a robust solution for anyone seeking to optimize mental performance and brain longevity. Zeranovia™ is a healthy weight loss enhancer, and Wynovia™ is used to help reduce the loss of lean muscle mass during dieting.

Beginning in April, the Company completed preparations to launch the Canine Product – PawPa® Regen. Backed by science and advanced technology, PawPa®'s products not only enhance pet wellness but also set the new standard in pet care. "Regen" dog chew PawPa®'s flagship product is crafted with a blend of advanced nutraceutical compounds and infused with all-natural ingredients; these chews are specially formulated to enhance canines' quality of life in their golden years. Specific benefits of the "Regen™" chew include Regenerative Support, Energy & Vitality, and Anti-aging Benefits.

The Company's Product MyndMed™ is completing its pre-launch phase. MyndMed™ is designed to optimize multiple neurotransmitter systems and neuroprotective pathways, delivering broad-spectrum cognitive benefits. By synergistically targeting acetylcholine, dopamine, neuroprotection, synaptic growth, and stress reduction, MyndMed™ supports both immediate and sustained improvements in mental performance, resilience, and brain health.

It aids in a rapid increase in motivation, sustained attention, and mental clarity, and helps in tackling demanding cognitive tasks with greater drive and efficiency. The product underwent rigorous testing by TruShield and received its TruShield Certified Certification, which provides the brand with a trusted, science-backed way to demonstrate that the product is free from banned substances.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#TOC)* |

---

Xcellara™ is BioAdaptives' regenerative wellness solution to enhance your performance, accelerate recovery, and revitalize your health. Backed by double-blind placebo-controlled clinical trials, Xcellara™ activates stem cells for cellular regeneration. Derived from a proprietary blend of nutraceutical compounds, Xcellara™ is the secret weapon for success on and off the court, providing a myriad of benefits. In its market testing, Xcellera™ has demonstrated a positive effect on individuals challenged by chronic fatigue.

Zeranovia™ has been going through a further refining process. It is about to complete its clinical trial for launching in the last quarter. Zeranovia™ is an innovative, natural weight loss supplement designed to work exceptionally well on its own or as a complement to GLP-1 and GIP weight loss treatments such as Ozempic, Wegovy, Zepbound, and Mounjaro. It supports weight loss by dramatically suppressing appetite, enhancing insulin sensitivity, preserving muscle mass, and delivering essential nutrients. Zeranovia™ significantly improves the effectiveness of existing treatments while providing substantial nutritional support to prevent muscle wasting during a caloric deficit. Throughout the trial, extremely encouraging results have been reported of participants losing 5 to 11 pounds in a 7 to 10 day period.

**(3) Results of Operations**

The Company has minimal revenues for years ended December 31, 2025, and December 31, 2024, of 18,278 and $12,669 respectively.

In conjunction with the Company's business plan, as discussed in Item I of this document, the Company has expended considerable effort and financial resources to the implementation of its business plan. The Company incurred operating expenses of $1,054688 which required cash payments of $516,254, which was principally funded through shareholder investments and loans as disclosed in the accompanying financial statement footnotes. The balance of the operating expenses was for activities that did not require cash payments, including stock-based compensation and a discount for amortization of debt.

Earnings (Loss) per share for the respective years ended December 31, 2023 and December 31, 2024, were $(0.15) and (0.11), respectively, based on the weighted-average shares issued and outstanding at the end of each respective period.

We anticipate that future expenditure levels will remain relatively consistent until such time that the Company fully implements its current business plan, at which time the Company's expenses and working capital requirements may increase significantly. The Company does not expect to generate any meaningful revenue or incur operating expenses for purposes other than fulfilling the obligations of a reporting company under the Exchange Act unless and until such time that the Company begins meaningful operations.

**(4) Plan of Business**

Subject to financing and various regulatory approvals, the Company intends to 1) market its existing products as described herein; 2) continue conducting research and investigation activities to identify new products or markets and improve its existing products and marketing; and 3) seek strategic or complimentary acquisitions in its current market space or, if indicated, others. There is no guarantee that the Company will be able to successfully implement this business plan or that if implemented, said plan will be successful.

**(5) Liquidity and Capital Resources**

On December 31, 2024 and 2025, respectively, the Company had working capital of approximately $225,901 and $261,885; inclusive of all related party accounts receivable, accrued expenses and line-of-credit notes payable.

It is the belief of management that our current finance partners, shareholders and the proceeds from our sales of Preferred D will be able provide sufficient working capital necessary to support and preserve the integrity of the corporate entity. However, there is no legal obligation for either management or significant stockholders to provide additional future funding and we cannot be assured as to the success of our offering. Further, the Company is at the mercy of future economic trends and business operations. Consequently, there is substantial doubt about the Company's ability to continue as a going concern.

The Company's need for working capital may change dramatically as a result of any future business transaction.

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#TOC)* |

---

There can be no assurance that the Company will identify or enter into any business transaction in the future. Further, there can be no assurance that the Company would be successful in consummating any acquisition on favorable terms or that it will be able to profitably manage the business, product, technology or company it acquires.

The Company has no current plans, proposals, arrangements or understandings with respect to the sale or issuance of additional securities prior to the location of a potential business transaction. Accordingly, there can be no assurance that sufficient funds will be available to the Company to allow it to cover the expenses related to such activities.

Regardless of whether the Company's cash assets prove to be inadequate to meet the Company's operational needs, the Company might seek to compensate providers of services by issuances of stock in lieu of cash.

**(6) Critical Accounting Policies**

Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("GAAP"). GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Our significant accounting policies are summarized in Note 2 of our financial statements. While all these significant accounting policies impact on our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause effect on our results of operations, financial position or liquidity for the periods presented in this report.

**Item 7A - Quantitative and Qualitative Disclosures about Market Risk** 

Not applicable

**Item 8 - Financial Statements and Supplementary Data** 

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#TOC)* |

---

**BIOADAPTIVES, INC**

**CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024**

---

| | |
|:---|:---|
| **TABLE OF CONTENT**  | **PAGE** |
| **[Report of Independent Registered Public Accounting Firm](#report) (PCAOB ID: 6993)** | F-2 |
| **[Consolidated Balance Sheet](#bs)** | F-3 |
| **[Consolidated Statements of Operations](#loss)** | F-4 |
| **[Consolidated Statements of Stockholders' Deficit](#defict)** | F-5 |
| **[Consolidated Statements of Cash Flows](#cf)** | F-6 |
| **[Notes to Consolidated Financial Statements](#notes)** | F-7 |

---

---

| |
|:---|
| F- 1 |
| *[**Table of Contents**](#TOC)* |

---

**Report of Independent Registered Public Accounting Firm**

The Board of Directors and Stockholders of

**BIOADAPTIVES, INC.**

<u>Opinion on the Financial Statements</u>

We have audited the accompanying consolidated balance sheets of **BioAdaptives, Inc** (the 'Company') as of December 31, 2025 and 2024, and the related consolidated statements of operations and comprehensive loss, changes in stockholders' equity/ (deficit) and cash flows for each of the two years in the period ended December 31, 2025 and 2024, and the related notes (collectively referred to as the "financial statements").

In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025 and 2024, in conformity with accounting principles generally accepted in the United States of America.

<u>Going Concern</u>

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company suffered an accumulated deficit of $(10,721,204), net loss of $(1,557,898) These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<u>Basis for Opinion</u>

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

<u>Critical Audit Matters</u>

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. Communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

**Accounting for Embedded Derivative Liabilities on Convertible Notes.**

As described in Note 7 to the financial statements, the Company issued several convertible notes that require complex accounting considerations and significant estimates. The Company concluded that certain variable conversion features embedded in these notes require classification as derivative liabilities. These features are initially measured at fair value. The Company determined the fair value of these embedded derivatives using the Black-Scholes model. The fair value of the embedded derivative liabilities related to the convertible notes was $1,738,804 as of December 31, 2025.

We identified the accounting considerations and related fair value measurements of these embedded derivative liabilities as a critical audit matter. Auditing these elements is especially challenging and requires significant auditor judgment due to the complexity of the instruments, the use of valuation models, and the need for specialized knowledge.

Our audit procedures related to the Company's accounting considerations and significant estimates included, among others:

· Reviewing the Company's analysis of the terms and features of the convertible notes and evaluating the accounting conclusions reached.

· Evaluating the identification and assessment of potential embedded derivatives and the determination of whether bifurcation was required.

· Assessing the determination of fair value for the debt and equity components and related conversion features, including evaluating the valuation models used and the reasonableness of key assumptions in light of current accounting guidance.

· Testing the mathematical accuracy of management's calculations related to the fair value estimates.

**/S/ Boladale Lawal**

**BOLADALE LAWAL & CO.** 

**(Chartered Accountants)**

**(PCAOB ID 6993)**

Lagos, Nigeria

We have served as the Company's auditor since 2024.

April 14, 2026

---

| |
|:---|
| F- 2 |
| *[**Table of Contents**](#TOCF)* |

---

**BIOADAPTIVES, INC.**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| **ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash | $158445 | $137470 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 44706 | 19115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security deposit | 2500 | 2500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expense | 6250 | 100000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other receivable | - | 2800 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 211901 | 261885 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 14000 | - |
| **TOTAL ASSETS** | $225901 | $261885 |
| **LIABILITIES AND STOCKHOLDERS' DEFICIT** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 232725 | 179458 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Derivative liabilities | 1738804 | 1053249 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible notes | 352332 | 461000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes Payable | 32096 | 32096 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 2355957 | 1725803 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | 2355957 | 1725803 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stockholders' Deficit: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, ($.0001 par value, 31,000,000 shares authorized; |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred Stock 4,000,000 shares designated; 11,167 issued and outstanding as of December 31, 2025 and 2024 | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series B Preferred Stock 5,000,000 shares designated; 9,667 share issued and outstanding as of December 31, 2025 and 2024 | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock 1,000,000 shares designated; 1,000,000 share issued and outstanding as of December 31, 2025 and 2024 | 100 | 100 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series D Preferred Stock 20,000,000 shares designated; 198,335 and 72,687 share issued and outstanding as of December 31, 2025 and 2024, respectively | 20 | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock ($.0001 par value, 1,250,000,000 shares authorized; 12,008,725 and 8,215,426 shares issued and outstanding as of December 31, 2025 and 2024, and 66 issuable, respectively) | 1200 | 821 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 8595711 | 7704343 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subscription receivable | (5885) | (5885) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (10721204) | (9163306) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total Stockholders' Deficit | (2130056) | (1463918) |
| **TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT** | $225901 | $261885 |

---

The accompanying notes are an integral part of these consolidated financial statements.

---

| |
|:---|
| F- 3 |
| *[**Table of Contents**](#TOCF)* |

---

**BIOADAPTIVES, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

---

| | | |
|:---|:---|:---|
|  | **Years ended** | **Years ended** |
|  | **December 31,**  | **December 31,**  |
|  | **2025** | **2024** |
| **Revenues** | $18278 | $12669 |
| Cost of revenue | 5781 | 8639 |
| **Gross Profit** | 12497 | 4030 |
| **Operating Expenses** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 820508 | 335306 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional fees | 230162 | 169523 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of inventory |  | 81350 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization and impairment loss of license and patent | 4000 | 19941 |
| **Total Operating Expenses** | 1054670 | 606120 |
| **Loss from operations** | (1042173) | (602090) |
| **Other Income (Expense)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income |  | 4950 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (70880) | (91978) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | (578645) | (210043) |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement of debt | 133800 | - |
| **Total Other Expense** | (515725) | (297071) |
| **Loss before income taxes** | (1557898) | (899161) |
| **Net Loss** | $(1557898) | $(899161) |
| **Net Loss Per Common Share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and Diluted | $(0.15) | $(0.11) |
| **Weighted Average Number of Common Shares Outstanding:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic and Diluted | 10072563 | 8215426 |

---

The accompanying notes are an integral part of these consolidated financial statements.

---

| |
|:---|
| F- 4 |
| *[**Table of Contents**](#TOCF)* |

---

**BIOADAPTIVES, INC.**

**CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT**

---

| | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series A Preferred stock** | **Series A Preferred stock** | **Series B Preferred stock** | **Series B Preferred stock** | **Series C Preferred stock** | **Series C Preferred stock** | **Series D Preferred stock** | **Series D Preferred stock** | **Common stock** | **Common stock** | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br>**paid-in**<br>**capital** | <br>**Subscription**<br> **receivable** | <br>**Accumulated**<br>**Deficit** | <br><br>**Total** |
| **Balance, December 31, 2023** | 9500 | $1 | 7500 | $1 |  | $- |  | $- | 5971728 | $597 | $6616915 | $- | $(8264145) | $(1646631) |
| Series A preferred stock issued for license fee | 1667 |  |  |  |  |  |  |  |  |  | 1500 |  |  | 1500 |
| Series B preferred stock issued for license fee |  |  | 1667 |  |  |  |  |  |  |  | 3000 |  |  | 3000 |
| Series B preferred stock issued for settlement of debt - related party |  |  | 500 |  |  |  |  |  |  |  | 1500 |  |  | 1500 |
| Series C preferred stock issued for purchase of inventory |  |  |  |  | 1000000 | 100 |  |  |  |  | 59900 |  |  | 60000 |
| Series D preferred stock issued for cash |  |  |  |  |  |  | 50000 | 5 |  |  | 299995 | (5885) |  | 294115 |
| Series D preferred stock issued for compensation |  |  |  |  |  |  | 22687 | 2 |  |  | 208869 |  |  | 208871 |
| Common stock issued for conversion of debt |  |  |  |  |  |  |  |  | 2239794 | 224 | 202419 |  |  | 202643 |
| Reverse split adjustment |  |  |  |  |  |  |  |  | 3904 |  |  |  |  |  |
| Debt forgiveness |  |  |  |  |  |  |  |  |  |  | 310245 |  |  | 310245 |
| Net loss for the period |  |  |  |  |  |  |  |  |  |  |  |  | (899161) | (899161) |
| **Balance, December 31, 2024** | 11167 | $1 | 9667 | $1 | 1000000 | $100 | 72687 | $7 | 8215426 | $821 | $7704343 | $(5885) | $(9163306) | $(1463918) |
| Common stock issued for conversion of Series D preferred stock |  |  |  |  |  |  | (8333) | (1) | 833300 | 83 | (82) |  |  |  |
| Series D preferred stock issued for compensation |  |  |  |  |  |  | 94113 | 10 |  |  | 414990 |  |  | 415000 |
| Series D preferred stock issued for cash |  |  |  |  |  |  | 39868 | 4 |  |  | 299996 |  |  | 300000 |
| Common stock issued for conversion of debt |  |  |  |  |  |  |  |  | 2960000 | 296 | 147794 |  |  | 148090 |
| Stock option compensation  |  |  |  |  |  |  |  |  |  |  | 28670 |  |  | 28670 |
| Reverse split adjustment |  |  |  |  |  |  |  |  | (1) |  |  |  |  |  |
| Net loss for the period |  |  |  |  |  |  |  |  |  |  |  |  | (1557898) | (1557898) |
| **Balance, December 31, 2025** | 11167 | $1 | 9667 | $1 | 1000000 | $100 | 198335 | $20 | 12008725 | $1200 | $8595711 | $(5885) | $(10721204) | $(2130056) |

---

The accompanying notes are an integral part of these consolidated financial statements.

---

| |
|:---|
| F- 5 |
| *[**Table of Contents**](#TOCF)* |

---

**BIOADAPTIVES, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOW**

---

| | | |
|:---|:---|:---|
|  | **Years ended** | **Years ended** |
|  | **December 31,**  | **December 31,**  |
|  | **2025** | **2024** |
| **CASH FLOWS FROM OPERATING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | $(1557898) | $(899161) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of derivative liabilities | 578645 | 210043 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bad debt | 2859 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of patent |  | 18000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of inventory |  | 81350 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of license and patent |  | 1941 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discount | 25132 | 52592 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management compensation | 443670 | 208871 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 4000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on settlement of debt | (133800) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (59) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (25591) | (25184) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expense | 93750 | 57200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 53267 | 44831 |
| Net Cash Used in Operating Activities | (516025) | (249517) |
| **CASH FLOWS FROM INVESTING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase property and equipment's | (18000) | - |
| Net Cash Used in Investing Activities | (18000) |  |
| **CASH FLOWS FROM FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of Series D Preferred Stock | 300000 | 294115 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from notes payable |  | 32096 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from convertible notes | 255000 | - |
| Net Cash Provided by Financing Activities | 555000 | 326211 |
| Net change in cash | 20975 | 76694 |
| Cash at beginning of period | 137470 | 60776 |
| Cash at end of period | $158445 | $137470 |
| **SUPPLEMENTAL CASH FLOW INFORMATION:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for income taxes | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $- | $- |
| **NON-CASH INVESTING AND FINANCING ACTIVITIES** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative liability recognized as debt discount | $255000 | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock for conversion of debt | $148090 | $202643 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock for conversion of debt | $150000 | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of Series A preferred stock for license fee | $- | $1500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of Series B preferred stock for license fee | $- | $3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of Series B preferred stock for settlement of debt - related party | $- | $1500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of Series C preferred stock for purchase of inventory | $- | $60000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible note issued for consulting service | $- | $150000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt forgiveness | $- | $310245 |

---

The accompanying notes are an integral part of these consolidated financial statements.

---

| |
|:---|
| F- 6 |
| *[**Table of Contents**](#TOCF)* |

---

**BIOADAPTIVES, INC.**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**1. <u>DESCRIPTION OF BUSINESS AND HISTORY</u>**

<u>Description of business</u>

BioAdaptives, Inc. ("BioAdaptives" or the "Company") was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company's control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. BioAdaptives' core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties.

The Company's corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

<u>Reverse stock split</u>

On November 20, 2024, the Company, filed with the Secretary of State of the State of Nevada, a Certificate of Change, pursuant to Nevada Revised Statutes 78.209, to effect a one-for-three hundred (1-for-300) reverse stock split (the "Reverse Stock Split") of the Company's issued and outstanding Common Stock, par value $0.001 per share. The Reverse Stock Split was effective as of November 21, 2024. This reverse stock split affected the voting rate and conversion rate of Preferred Stock except for Series C Preferred Stock.

All share and per share information in these financial statements retroactively reflect this reverse stock split.

<u>Stock Dividend</u>

On December 2, 2024, the Company approved the issuance of stock dividends. Each Common Stockholder received one (1) additional share of Common Stock for each share owned. The Company account for this stock dividend as forward stock split

All share and per share information in these financial statements retroactively reflect this stock dividend.

**2. <u>SUMMARY OF SIGNIFICANT POLICIES</u>**

<u>Basis of Presentation</u>

The Company represents its consolidated financial statements were prepared in accordance with US GAAP and the rules of the Securities and Exchange Commission and that, in the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations are historical and not necessarily indicative of the results to be expected for any future period.

<u>Use of estimates</u>

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

---

| |
|:---|
| F- 7 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Cash and cash equivalents</u>

Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high-credit-quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value. As of December 31, 2025 and 2024, the Company had $215,205 and $261,885 cash, respectively. As of December 31, 2025 and 2024, the Company did not have cash equivalents.

<u>Accounts Receivable and Allowance for Uncollectible Accounts</u>

Substantially all of the Company's accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in its existing accounts receivable. The Company reviews its allowance for doubtful accounts daily and past due balances and a specified amount are reviewed individually for collectability. Account balances are charged off after all means of collection have been exhausted and the potential for recovery is considered remote. During the years ended December 31, 2025 and 2024, the Company record bad debt expense of $2,859 and $0, respectively.

<u>Inventory</u>

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As of December 31, 2025 and 2024, the Company had inventory as follows, and determined that no reserve was required.

---

| | | |
|:---|:---|:---|
|  | December 31,<br>2025 | December 31,<br>2024 |
| Finished goods | $35207 | $- |
| Raw material | 9499 | 19115 |
|  | $44706 | $19115 |

---

<u>Property and Equipment</u>

Property and equipment are carried at cost less accumulated depreciation. Depreciation is provided over the assets' estimated useful lives, using the straight-line method. Currently our assets consist of mobile warehouse which we amortize over a useful life of 3 years.

Maintenance and repairs are charged to expenses as incurred. Improvements of a major nature are capitalized. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any gains or losses are reflected in income

---

| |
|:---|
| F- 8 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Intangible assets</u>

Intangible assets with an indefinite life are not amortized and are tested for impairment annually or more frequently if events or changes in circumstances indicate that they might be impaired.

Intangible assets with finite lives are initially recorded at cost and amortized on a straight-line basis over the estimated economic useful lives of the respective assets.

We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.

<u>Financial Instruments and Fair Value Measurements</u>

As defined in ASC 820" Fair Value Measurements," fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The following table summarizes fair value measurements by level as of December 31, 2025 and 2024, measured at fair value on a recurring basis:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Total Carrying Value**<br>**as of December 31,**<br>**2025** | **Quoted Market Prices in Active Markets**<br>**(Level 1)** | **Significant Other Observable Inputs**<br>**(Level 2)** | **Significant Unobservable Inputs**<br>**(Level 3)** |
| **Assets:** |  |  |  |  |
| Equity Securities | $- | $- | $- | $- |
| **Liabilities** |  |  |  |  |
| Derivative liabilities | $1738804 | $- | $- | $1738804 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Total Carrying Value** <br>**as of December 31, 2024** | **Quoted Market Prices in Active Markets**<br>**(Level 1)** | **Significant Other Observable Inputs**<br>**(Level 2)** | **Significant Unobservable Inputs**<br>**(Level 3)** |
| **<u>Assets:</u>** |  |  |  |  |
| Equity Securities | $- | $- | $- | $- |
| Total | $- | $- | $- | $- |
| **<u>Liabilities</u>** |  |  |  |  |
| Derivative liabilities | $1053249 | $- | $- | $1053249 |

---

---

| |
|:---|
| F- 9 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Derivative Financial Instruments</u>

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

<u>Revenue recognition</u>

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

· identify the contract with a customer;

· identify the performance obligations in the contract;

· determine the transaction price;

· allocate the transaction price to performance obligations in the contract; and

· recognize revenue as the performance obligation is satisfied.

<u>Cost of revenue</u>

Cost of revenue includes the inventory purchased from a related party.

<u>Stock-based compensation</u>

The Company accounts for stock-based compensation arrangements with employees, nonemployee directors and consultants using a fair value method, which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options, on a straight-line basis over the requisite service period in the Company's consolidated statements of operations. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant.

<u>Concentration of credit risk</u>

Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.

---

| |
|:---|
| F- 10 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Income taxes</u>

The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes require a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more- likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company's experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.

The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the financial results of operations improve, and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance.

Significant judgment is required in evaluating the Company's tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.

<u>Earnings (loss) per share</u>

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued.

For the years ended December 31, 2025 and 2024, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

---

| | | |
|:---|:---|:---|
|  | December 31,<br>2025 | December 31,<br>2024 |
|  | (Shares)  | (Shares)  |
| Series A Preferred Stock | 55835 | 55835 |
| Series B Preferred Stock | 96670 | 96670 |
| Series C Preferred Stock | 100000000 | 100000000 |
| Series D Preferred Stock | 19832833 | 4792339 |
| Convertible notes | 70231836 | 6185001 |
| Total | 190217174 | 111129840 |

---

---

| |
|:---|
| F- 11 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Lease</u>

The Company leases office space for corporate activities.

In accordance with ASC 842, "*Leases,*" we determine if an arrangement is a lease at inception.

The office lease meets the definition of a short-term lease because the lease term is 12 months or less. Consequently, consistent with Company's accounting policy election, the Company does not recognize the right-of-use asset and the lease liability arising from this lease.

***Recent Accounting Pronouncements***

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

**3. <u>GOING CONCERN</u>**

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $10,721,204 as of December 31, 2025. The Company requires capital for its contemplated operational and marketing activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company's contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

**4. <u>PREPAID EXPENSE</u>**

In November 2024, the Company entered into a consulting agreement with a six-month term. The Company shall pay $150,000 as one-time compensation for our convertible note for consulting services upon execution of the agreement. Additionally, the Company will pay consulting fee of $5,000 per month.

As of December 31, 2025 and 2024, the Company recorded prepaid expense of $6,250 for OTC annual fee and $100,000 as prepaid profession fee, respectively.

---

| |
|:---|
| F- 12 |
| *[**Table of Contents**](#TOCF)* |

---

**5. <u>ACCOUNTS PAYABLE AND ACCRUED LIABILITIES</u>**

Accounts payable and accrued liabilities aa of December 31, 2025 and 2024 consists of the following:

---

| | | |
|:---|:---|:---|
|  | December 31,<br>2025 | December 31,<br>2024 |
| Accounts payable | $13513 | $5999 |
| Accrued interest | 218189 | 172438 |
| Accrued liabilities | 1023 | 1021 |
|  | $232725 | $179458 |

---

**6. <u>CONVERTIBLE NOTES</u>**

Convertible notes as of December 31, 2025 and 2024 consist of the following:

---

| | | |
|:---|:---|:---|
|  | December 31,<br>2025 | December 31,<br>2024 |
| Convertible Notes - originated in April 2018 | $95000 | $95000 |
| Convertible Notes - originated in June 2018 | 166000 | 166000 |
| Convertible Notes - originated in October 2018 | 50000 | 50000 |
| Convertible Notes - originated in November 2024 | 16200 | 150000 |
| Convertible Notes - originated in November 2025 | 295000 | - |
| Total convertible notes payable | 622200 | 461000 |
| Less: Unamortized debt discount | (269868) | - |
| Total convertible notes | 352332 | 461000 |
| Less: current portion of convertible notes | 352332 | 461000 |
| Long-term convertible notes | $- | $- |

---

For the years ended December 31, 2025 and 2024, the interest expense on convertible notes was $44,466 and $38,278, respectively. As of December 31, 2025 and 2024, the accrued interest was $215,973 and $171,507, respectively.

The Company recognized amortization expense related to the debt discount of $25,132 and $52,592 for the years ended December 31, 2025 and 2024, respectively, which is included in interest expense in the statements of operation.

*Conversion*

During the year ended December 31, 2025, the note holder converted principal amounts of $133,800 into 2,960,000 shares of common stock. As a result, the Company settled convertible notes, and derivative liability of $133,800, and recorded gain on settlement of debt of $133,800.

During the year ended December 31, 2024, the Company converted notes with principal amounts of $63,250 and accrued interest of $4,726 into 2,239,792 shares of common stock. The corresponding derivative liability at the date of conversion of $134,666 was credited to additional paid in capital.

*Convertible Notes – Issued during the year ended December 31, 2025*

During the year ended December 31, 2025, the Company issued a total principal amount of $295,000 in convertible notes for cash proceeds of $255,000. The terms of these convertible notes are summarized as follows:

---

| |
|:---|
| F- 13 |
| *[**Table of Contents**](#TOCF)* |

---

---

| |
|:---|
| Term 1 year; |
| Annual interest rates 6 - 10%; |
| Convertible at the option of the holders at any time |
| Conversion prices are based on 60 - 65% of the lowest traded price for the common stock during 20-trading days. |

---

In addition, the Company issued a total of 2,062,500 warrants in connection with certain convertible notes. The warrants will expire 3 years after issuance date, and the exercise price of $0.08. The Company determined that the warrants had a fixed monetary value with a variable number of shares at inception and categorized the warrants as a liability, which his derivative liability on the balance sheet.

*Convertible Notes – Issued during the year ended December 31, 2024*

On November 5, 2024, the Company issued convertible note of $150,000 for consulting service. The convertible note has a term of 6 months, at an interest rate of 6% per annum. The outstanding principal amount of convertible note and unpaid interest are convertible at the option of the holder at 6 months after the issue date. The conversion price is an average of the closing price during the previous 15-trading days.

*Convertible Notes – Issued during the year ended December 31, 2018*

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of 713 common shares valued at $22,210. The terms of these convertible notes are summarized as follows:

---

| |
|:---|
| Term two years; |
| Annual interest rates 12%; |
| Convertible at the option of the holders at any time |
| Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price. |

---

**7. <u>DERIVATIVE LIABILITIES</u>**

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

*Fair Value Assumptions Used in Accounting for Derivative Liabilities.*

ASC 815 requires us to assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

---

| |
|:---|
| F- 14 |
| *[**Table of Contents**](#TOCF)* |

---

The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black-Scholes pricing model to calculate the fair value as of December 31, 2025. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

For the years ended December 31, 2025 and 2024, the estimated fair values of the liabilities measured on a recurring basis are as follows:

---

| | | |
|:---|:---|:---|
|  | Year ended<br>December 31,<br>2025 | Year ended <br>December 31,<br>2024 |
| Expected term | 0.90 - 3.00 years  | 0.22- 0.46 years  |
| Expected average volatility | 283% - 301% | 231% - 294% |
| Expected dividend yield |  |  |
| Risk-free interest rate | 3.47 %- 3.61% | 5.25% - 5.48% |

---

The following table summarizes the changes in the derivative liabilities during the years ended December 31, 2025 and 2024.

---

| | |
|:---|:---|
| Fair Value Measurements Using Significant Observable Inputs (Level 3) | Fair Value Measurements Using Significant Observable Inputs (Level 3) |
| Balance - December 31, 2023 | $977872 |
| Settled on issuance of common stock | (134666) |
| Loss on change in fair value of the derivative | 210043 |
| Balance - December 31, 2024 | $1053249 |
| Addition of new derivatives recognized as debt discounts | 210293 |
| Addition of new derivatives recognized as warrants | 44707 |
| Addition of new derivatives recognized as loss on derivatives | 430425 |
| Settled on issuance of common stock | (148090) |
| Loss on change in fair value of the derivative | 148220 |
| Balance - December 31, 2025 | $1738804 |

---

The aggregate loss on derivatives during the years ended December 31, 2025 and 2024 was as follows.

---

| | | |
|:---|:---|:---|
|  | Years ended | Years ended |
|  | December 31, | December 31, |
|  | 2025 | 2024 |
| Day one loss due to derivative liabilities on convertible notes | $430425 | $- |
| Loss on change in fair value of the derivative liabilities | 148220 | 210043 |
|  | $578645 | $210043 |

---

---

| |
|:---|
| F- 15 |
| *[**Table of Contents**](#TOCF)* |

---

**8. <u>STOCKHOLDERS' EQUITY</u>**

<u>Preferred Stock</u>

On March 13, 2025, the increase in number of preferred shares from 10,000,000 to 31,000,000 having the par value of 0.0001 per share was authorized by written consent of the holders of a majority of our outstanding voting stock.

The Company is authorized to issue 31,000,000 shares of preferred stock, $0.001 par value per share, of which 4,000,000 have been designated as Series A Preferred Stock, 5,000,000 have been designated as Series B Preferred Stock, 1,000,000 have been designated as Series C Preferred Stock and 20,000,000 have been designated as Series D Preferred Stock.

<u>Series A Preferred Stock</u>

On February 6, 2020, the Company established its Series A Preferred Stock, par value $0.001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company's board exercised "blank check" authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.

The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders' option; and conversion-to-common rights at a 5:1 ratio.

During the year ended December 31, 2024, the Company issued 500,000 shares of Series A Preferred Stock valued at $1,500 for license fee.

As of December 31, 2025 and 2024, 11,167 shares of Series A Preferred Stock are issued and outstanding.

<u>Series B Preferred Stock</u>

On January 24, 2022, the Company established its Series B Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company's board exercised "blank check" authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 5,000,000 shares of Series B Preferred Stock.

The Company may use the Series B Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series B Preferred Stock have enhanced voting privileges (10:1); the collective right to appoint elect one director, at the Holders' option; and conversion-to-common rights at a 10:1 ratio.

During the year ended December 31, 2024, the Company issued 1,667 shares of Series B Preferred Stock valued at $3,000 for license fee.

During the year ended December 31, 2024, the Company issued 500 shares of Series B Preferred Stock valued at $1,500 for settlement of note payable – related party and interest of $860 and $640, respectively.

As of December 31, 2025 and 2024, 9,667 shares of Series B Preferred Stock are issued and outstanding.

---

| |
|:---|
| F- 16 |
| *[**Table of Contents**](#TOCF)* |

---

<u>Series C Preferred Stock</u>

On January 24, 2022, the Company established its Series C Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company's board exercised "blank check" authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 1,000,000 shares of Series C Preferred Stock.

The Company may use the Series C Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series C Preferred Stock have enhanced voting privileges (1000:1); the collective right to appoint elect one director, at the Holders' option; and conversion-to-common rights at a 100:1 ratio.

During the year ended December 31, 2024, the Company issued 1,000,000 shares of Series C Preferred Stock valued at $60,000 for purchase of inventory.

As of December 31, 2025 and 2024, 1,000,000 shares and 0 shares of Series C Preferred Stock are issued and outstanding, respectively.

<u>Series D Preferred Stock</u>

On July 4, 2024, the Company established its Series D Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company's board exercised "blank check" authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series D Preferred Stock.

The may convert the Series D Preferred Stock to Common Stock at a rate of 100 shares of common stock for each share of Series D Preferred Stock. Each Series D Preferred Stock carries the voting rights equal to 100 shares of Common Stock.

During the year ended December 31, 2025, the Company issued 94,113 shares of Series D Preferred stock valued at $415,000 for compensation.

During the year ended December 31, 2025, one shareholder converted 8,333 shares of Series D Preferred stock to 833,300 shares of common stock.

During the year ended December 31, 2025, the Company issued 39,868 shares of Series D Preferred stock in cash for subscription of $300,000.

During the year ended December 31, 2024, the Company issued 16,667 shares of Series D Preferred Stock for cash valued at $100,000 to Gimhana Dissanayake and John Keener.

During the year ended December 31, 2024, the Company issued 33,333 shares of Series D Preferred Stock for cash valued at $200,000 to Mary Wilkins. The Company received $194,115, $19,115 of which is related to inventory purchased from a vendor paid on behalf of the Company. The remaining $5,885 is classified as subscription receivable as of December 31, 2024.

During the year ended December 31, 2024, the Company issued 22,687 shares of Series D Preferred Stock for compensation of James Keener and Gimhana Dissanayake valued at $208,871.

---

| |
|:---|
| F- 17 |
| *[**Table of Contents**](#TOCF)* |

---

As of December 31, 2025 and 2024, 198,335 and 72,687 shares of Series D Preferred Stock are issued and outstanding, respectively.

<u>Common Stock</u>

The Company is authorized to issue 1,250,000,000 shares of Common Stock, $0.001 par value per share.

As of December 31, 2025 and 2024, there were 12,008,725 and 8,215,426 shares of the Company's common stock issued and outstanding, respectively. In addition, as of December 31, 2025 and 2024, there were 66 shares of the Company's common stock issuable.

*Fiscal year 2025*

During the year ended December 31, 2025, the Company issued Common shares as follows;

· 2,960,000 shares of common stock for conversion of debt.

· 833,330 shares of common stock valued for conversion of Series D Preferred stock.

*Fiscal year 2024*

During the year ended December 31, 2024, the Company issued Common shares as follows;

· 2,239,794 shares of common stock valued at $202,643 for conversion of debt.

· Reverse stock split adjustment of 3,904.

***Stock Option***

On April 16, 2025, the Company granted stock option of 500,000 shares of common stock to our director for compensation, valued at $28,670 with term of ten years, exercise price of $10.00 per share, fully vested on grant date. During the year ended December 31, 2025, the Company recognized stock option expense of $28,670.

The following is a summary of the change in stock option during the year ended December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
|  | Options Outstanding | Options Outstanding | |
|  | Number of<br>Options | Weighted Average<br>Exercise Price | Weighted Average<br>Remaining life <br>(years) |
| Outstanding, December 31, 2024 |  | $- |  |
| Granted | 500000 | 10.00 | 10.01 |
| Exercised |  |  |  |
| Forfeited/canceled | - | - | - |
| Outstanding, December 31, 2025 | 500000 | $10.00 | 9.30 |
| Exercisable options, December 31, 2025 | 500000 | $10.00 | 9.30 |

---

The intrinsic value of the options as of December 31, 2025, is $0.

---

| |
|:---|
| F- 18 |
| *[**Table of Contents**](#TOCF)* |

---

**9. <u>RELATED PARTY TRANSACTIONS</u>**

<u>Due to related party</u>

During the year ended December 31, 2024, accounts payable of $2,729 was paid by a related party and due to related party of $5,106 was forgiven.

As of December 31, 2025 and 2024, the Company owed Dr. Edward E. Jacobs, M.D., $0.

<u>Employee agreements</u>

In May 2024, the Company entered into an employment agreement as our chief executive officer. The Company agrees to pay a salary of $300,000 per annum. During the years ended December 31, 2055 and 2024, the Company recorded payroll expense of $300,000 and $158,871 and the Company issued 68,858 and 18,062 shares of Series D Preferred Stock for payroll, respectively.

In May 2024, the Company entered into an employment agreement as our director with a one-year term. The Company agrees to pay a salary of $5,000 per month. During the years ended December 31, 2025 and 2024, the Company recorded payroll expense of $60,000 and $50,000 and the Company issued 13,102 and 4,625 shares of Series D Preferred Stock for payroll, respectively.

In January 2025, the Company entered into an employment agreement as our director. The Company agrees to pay a salary of $5,000 per month. During the year ended December 31, 2025, the Company recorded payroll expenses of $55,000 for a director and the Company issued 12,153 shares of Series D Preferred Stock for payroll.

<u>License</u> 

The term of licenses is a range from 1 to 3 years for certain products. The Company agrees to pay a royalty on sales of the Products during the term of licensee's equivalent to 2 – 5% of gross product sales amounts ("GPSA"). Such royalty shall be payable only after the Licensor attains a GPSA of $20,000 to $30,000 in any calendar month and shall be payable on the entire GPSA for such period.

For the year ended December 31, 2024, the Company recorded amortization expense of $1,941 and impairment loss $18,000. As of December 31, 2024, license was fully impaired.

**10. <u>NOTES PAYABLE</u>**

During the year ended December 31, 2024, the Company issued notes payable – related party of $32,096. The note is a 4% interest bearing promissory note that the term is 1 year.

During the year ended December 31, 2024, the Company repaid notes payable to a related party of $860 and recognized interest of $177. The note is a 4% interest bearing promissory note that the term is 1 year.

During the year ended December 31, 2024, notes payable to a related party of $4,283 and accrued interest of $856 were forgiven and the balance of notes payable and accrued interest as of December 31, 2024 were $0.

---

| |
|:---|
| F- 19 |
| *[**Table of Contents**](#TOCF)* |

---

During the year ended December 31, 2025 and 2024, the Company recorded interest expense of $1,285 and $931, respectively, and recorded notes payable of $32,096, and accrued interest of $2,216 and $931, respectively, as of December 31, 2025 and 2024.

**11. <u>PROVISION FOR INCOME TAXES</u>**

The Company provides for income taxes under ASC 740," Income *Taxes."* Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation

allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 21% to the net loss before provision for income taxes for the following reasons:

---

| | | |
|:---|:---|:---|
|  | December 31,<br>2025 | December 31,<br>2024 |
| Net operating loss | $(200260) | $(133670) |
| Valuation allowance | 200260 | 133670 |
| Income tax expense per books | $- | $- |

---

The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows:

---

| | | |
|:---|:---|:---|
|  | December 31,<br>2025 | December 31,<br>2024 |
| NOL Carryover | $919097 | $718837 |
| Valuation allowance | (919097) | (718837) |
| Net deferred tax asset | $- | $- |

---

Due to the change in ownership provisions of the Income Tax laws of the United States of America, net operating loss carry forwards of approximately $4.4 million for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited to use in future years.

**12. <u>COMMITMENTS AND CONTINGENCIES</u>**

Short-term Leases

The Company has not entered into any long-term leases, contracts, or commitments. In November 2023, the Company leased an office for a month-to-month term. During the years ended December 31, 2025 and 2024, the Company incurred rent expense of $225 and $2,132, respectively. The Company recorded a security deposit of $2,500 as of December 31, 2025 and 2024.

**13. <u>SUBSEQUENT EVENTS</u>**

In January, the Company worked with River Inn to test a new Canine product for calming and stress. This is intended to explore a new item for PawPa® extending to the travelling markets. In March, PawPa® was granted its TradeMark for its products.

---

| |
|:---|
| F- 20 |
| *[**Table of Contents**](#TOCF)* |

---

**PART III**

**Item 10 Directors, Executive Officers and Corporate Governance**

The following information sets forth the names, ages, and positions of our current directors and executive officers as of December 31, 20242.

---

| | | |
|:---|:---|:---|
| Name | Age | Principal Positions with Us |
| James E. Keener | 55 | Chairman & Chief Executive Officer |
| Gimhana Dissanayake | 53 | Director |
| Mark Frissora | 60 | Director |

---

Biographical Information for James E. Keener

James E Keener, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age 55 . Chairman and Chief Executive Officer

James Keener, CEO of BioAdaptives, Inc., is a highly accomplished executive with a diverse and impressive career spanning multiple industries. He has been leading strategic growth initiatives since his appointment in May 2024. His leadership at BioAdaptives emphasizes leveraging the company's strengths in research-driven nutritional products to enhance health and wellness, focusing on expanding market presence and driving innovation.

Before his role at BioAdaptives, Keener was the CEO of a private investment company. He managed a wide range of businesses, such as retail locations, hotels and hospitality, agriculture, and forestry operations, with domestic and international reach. This role showcased his ability to handle complex, multifaceted asset management and deliver results across diverse sectors.

Earlier in his career, Keener established himself as a renowned turnaround specialist in the air freight industry. As a performance specialist, he focused on revitalizing underperforming contracts across the United States, demonstrating his strategic thinking and ability to optimize business operations in high-pressure environments.

Keener's professional journey began with a foundation of public service as a firefighter in Stockton, California. This early role reflects his commitment to community and leadership under challenging conditions, qualities that have carried through his subsequent career achievements.

With a proven track record as a marketer, innovator, and turnaround expert, James Keener brings a wealth of experience to every endeavor. He blends operational transformation skills with a strategic focus on growth and profitability. His career trajectory—from firefighter to CEO of a publicly traded company—illustrates his remarkable ability to adapt, lead, and succeed across varied industries.

Biographical Information for Gimhana Dissanayake

Gimhana Dissanayake, Age 52 , Director

Gimhana Dissanayake, currently serves as the Vice President of Operations and Sales for North America at The Hertz Corporation (NYSE: HTZ), bringing over two decades of comprehensive experience and a proven track record of strategic growth and operational excellence to BioAdaptives.

---

| |
|:---|
| 19 |
| *[**Table of Contents**](#TOC)* |

---

With an illustrious career that spanned various leadership roles at Hertz, Gimhana is renowned for his strategic vision and leadership acumen. He has been instrumental in advancing the Hertz, Dollar, and Thrifty brands, significantly enhancing their market presence and competitive edge. As the Senior Director of Strategic Partnerships, he spearheaded initiatives that fostered key alliances and drove substantial growth across 10 revenue verticals in North America. His efforts earned him the nickname' Founder of Canada' within Hertz, a testament to his successful expansion of the company's market share in the region. His strategic prowess is a valuable asset that will undoubtedly benefit BioAdaptives.

Gimhana's educational background and extensive professional experience make him an invaluable addition to the BioAdaptives board. He holds an undergraduate degree from Oklahoma State University and an MBA from California State University - Sacramento. In addition, he has completed advanced executive education at Cornell University and the Wharton School of Business.

Biographical Information for Mark P. Frissora

Mark P. Frissora, Age 60, Director

Mark Frissora, most recently the CEO and President of Caesars Entertainment, has 42 years of business experience across managerial and functional roles. He joined Caesars in 2015 and previously served as Chairman and CEO of Hertz Global Holdings and Tenneco, Inc., leading both Fortune 500 companies through transformative growth.

Frissora has a 20-year track record of creating stakeholder value at highly leveraged companies in private equity and public markets, meeting or exceeding expectations in over 92% of 65 quarters during two significant recessions. He led two companies through successful IPOs and guided Caesars out of bankruptcy to its NASDAQ relisting in 2017. At Tenneco, where he served as Chairman and CEO from 1999 to 2006, shareholder value tripled, revenue rose 39%, and the company earned top industry awards for shareholder returns.

During his tenure at Hertz from 2006 to 2014, shareholders saw a 3.6x return post-IPO, with a special dividend paid after the launch. At Caesars, he drove initiatives that increased EBITDA by $812M (55%) and margins by 930 bps, creating $12.5B in value during its bankruptcy turnaround. Frissora currently chairs Arencibia, an advanced engineering company, and co-founded Goodwrx, a gig economy technology solution. He previously served on the boards of Caesars Entertainment, Aptiv, Walgreens Boots Alliance, FMC Corporation, and NCR Corporation, holding key leadership roles on governance, compensation, and finance committees. Mark holds a B.A. from The Ohio State University and has completed executive programs at Babson College and Thunderbird School of Global Management.

Advisory Board

The Company uses an Advisory Board to assist the officers and directors with regard to specific scientific and administrative matters. These advisors did not meet during the period ended December 31, 2020, and we did not call on them due to a lack of need.

---

| | | |
|:---|:---|:---|
| Name | Age | Principal Positions with Us |
| Reed Harris | 69 | Advisor |

---

Reed Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship (UFC) in Las Vegas, has a distinguished career spanning over 40 years. He blends expertise in martial arts, business development, and charity work. His life and career reflect a dedication to discipline, growth, and giving back to the community.

Harris works closely with BioAdaptives to introduce new products geared to repair and recover both body and mind after extreme workouts. Reed's exceptional leadership, business acumen, and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions. His deep experience building and managing successful organizations and his passion for helping others makes him an invaluable asset to BioAdaptives as we expand our reach and impact.

**Term of Office**

Our Directors are appointed for a one-year term but will hold office until the next annual general meeting of our shareholders or until removed from office by our bylaws. Our board of directors appoints our officers and holds office until removed by the board.

---

| |
|:---|
| 20 |
| *[**Table of Contents**](#TOC)* |

---

**Family Relationships**

None.

**Involvement in Certain Legal Proceedings**

To the best of our knowledge, during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

**Committees of the Board**

Our company currently does not have nominating, compensation or audit committees or committees performing neither similar functions nor does our company have a written nominating, compensation, or audit committee charter. Our directors believe that it is not necessary to have such committees, at this time, because the board of directors can adequately perform the functions of such committees. Our Common Stock trades on the OTC Bulletin Board, which does not impose standards relating to director independence or the makeup of committees with independent directors, or provide definitions of independence

Our company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The board of directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees. The board of directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our President, James E.Keener, at the address appearing on the first page of this annual report.

**Financial Expert**

The Company does not have a designated "financial expert" on the Board of Directors. We believe that the cost of obtaining and retaining an independent director who can also serve as our financial expert is prohibitive.

**Information Concerning Non-Director Executive Officers**

Mr. James E Keener has an employment contract with the Company, under which he is compensated with cash or stock as he elects.

**Code of Ethics**

As of December 31, 2024, we had not adopted a Code of Ethics for Financial Executives, which would include our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Potential Conflict of Interest

Since we do not have an audit or compensation committee comprised of independent directors, the functions that would have been performed by such committees are performed by our Board of Directors. Thus, there is a potential conflict of interest in that our directors have the authority to determine issues concerning management compensation, including their own, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our officers or directors.

**Board's Role in Risk Oversight**

The Board of Directors assesses on an ongoing basis the risks faced by BioAdaptives. These risks include financial, technological, competitive, and operational risks. The Board dedicates time at each of its meetings to review and consider the relevant risks faced at that time. In addition, since the Company does not have an Audit Committee, the Board of Directors is also responsible for the assessment and oversight of our financial risk exposures.

---

| |
|:---|
| 21 |
| *[**Table of Contents**](#TOC)* |

---

**Compliance With Section 16(a) of the Exchange Act**

Section 16(a) of the Exchange Act requires the Company's directors, executive officers and persons who own more than ten percent of a registered class of the Company's equity securities ("10% holders"), to file with the Securities and Exchange Commission (SEC) initial reports of ownership and reports of changes in ownership of Common stock and other equity securities of the Company.

Directors, officers and 10% holders are required by SEC Regulation to furnish the Company with copies of all of the Section 16(a) reports they file. Based solely on a review of reports furnished to the Company and/or written representations from the Company's directors and executive officers during the fiscal year ended December 31, 2020, there was no compliance with the Section 16(a) filing requirements applicable to its directors, officers and 10% holders for such year.

**Involvement on Certain Material Legal Proceedings During the Past Five (5) Years**

(1) No director, officer, significant employee or consultant has been convicted in a criminal proceeding, exclusive of traffic violations or is subject to any pending criminal proceeding.

(2) No bankruptcy petitions have been filed by or against any business or property of any director, officer, significant employee or consultant of the Company nor has any bankruptcy petition been filed against a partnership or business association where these persons were general partners or executive officers.

(3) No director, officer, significant employee or consultant has been permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of business, securities or banking activities.

(4) No director, officer or significant employee has been convicted of violating a federal or state securities or commodities law.

**Item 11. Executive Compensation**

We have employment agreements with our Chief Executive Officer, who was to be compensated by cash or stock grants.

The Company has no other executive compensation issues which would require the inclusion of other mandated table disclosures.

**Director Compensation**

Our directors' compensation is wholly derived from their Director's agreement as set out above.

---

| |
|:---|
| 22 |
| *[**Table of Contents**](#TOC)* |

---

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

The following table sets forth certain information as of December 31, 2024, regarding the number of shares of Common Stock beneficially owned by (i) each person or entity known to us to own more than five percent of our Common Stock; (ii) each of our Named Executive Officers; (iii) each of our directors; and (iv) all of our executive officers and directors as a group. The percentages are based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; total outstanding Shares as of December 31, 2024.

Except as otherwise noted, the persons named in the table have sole voting and dispositive power with respect to all shares beneficially owned, subject to community property laws where applicable.

As of December 31, 2025

---

| | | | |
|:---|:---|:---|:---|
| Title of class | Name of beneficial owner | Amount of beneficial ownership | Percent of class |
| Series C | James E Keener | 1,000,000 shares | 100% |
| Series D | James E Keener | 86,621 shares | 24.8% |
|  | Chairman & Chief Executive Officer |  |  |
| Series D | Gimhana Dissanayake | 26.060 shares | 17.8% |
|  | Director |  |  |
| Series D | Mark P. Frissora | 52,021share |  |

---

All Officers and Directors as a Group (3 persons)

**Changes in Control**

On June 21, 2013, the Company's sole officer, director and shareholder, Richard Chiang, sold 10,000,000 shares of the Company's common stock, constituting 100% of its issued and outstanding shares, to Ferris Holding Inc., a Nevada corporation ("FHI") for a purchase price of $40,000. Effective the same date, Mr. Chiang or the Company appointed Barry K. Epling, who was the sole shareholder of FHI, as Chairman of the Board of Directors, and Gerald A. Epling as its President, Chief Executive Officer, Secretary, Chief Financial Officer and a director; Mr. Chiang then resigned. On September 25, 2013, the Company changed its name to BioAdaptives, Inc.

On October 2, 2017, the Board of Directors appointed Kim Southworth and Dr. Edward E Jacobs, Jr MD as directors and Barry K. Epling resigned as Chairman. FHI donated 9,628.568 shares of the Company's common stock to the Breath of Life Foundation, a Section 501(c)(3) non-profit organization. At that time, these shares constituted 51.84% of the Company's issued and outstanding shares and, as part of the grant, Breath of Life granted the Company's Board of Directors an irrevocable proxy to vote them. With these actions, Barry K. Epling terminated his relationship with the Company as an owner (direct or indirect), officer or director

September 2018,

Subsequent to the establishment of the Series A-B-C-D Preferred Stock, the enhanced voting privileges provided to the Series A-B-C-D Preferred Stockholders will provide them with sufficient voting authority to exercise control over the Company's corporate functions. Currently, the control voting privileges are held with the Preferred Series C voting rights owned by James E. Keener.

---

| |
|:---|
| 23 |
| *[**Table of Contents**](#TOC)* |

---

**Item 13 - Certain Relationships and Related Transactions, and Director Independence**

Relationships and Transactions

Independence Transactions with Related Persons

Azuna Health

Conflicts of Interest

Certain conflicts of interest could arise in the future, including, but not limited to, the following:

\* None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating management time among various business activities.

\* In the course of their other business activities, our officers and directors may become aware of investment and business opportunities that may be appropriate for presentation to us as well as the other entities with which they are affiliated. They may have conflicts of interest in determining to which entity a particular business opportunity should be presented.

\* Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by us.

\* Since all of our directors own shares of our common stock that could be sold, in whole or in part, as a negotiated element of a business acquisition, our board may have a conflict of interest in determining whether a particular target business is appropriate to effect a business combination. The personal and financial interests of our directors and officers may influence their motivation in identifying and selecting a target business and completing a business combination.

In general, officers and directors of a Delaware corporation are required to present business opportunities to a corporation if:

\* the corporation could financially undertake the opportunity.

\* the opportunity is within the corporation's line of business; and

\* it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.

---

| |
|:---|
| 24 |
| *[**Table of Contents**](#TOC)* |

---

Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. In addition, conflicts of interest may arise when our board evaluates a particular business opportunity with respect to the above-listed criteria. We cannot assure you that any of the above-mentioned conflicts will be resolved in our favor.

**Director Independence**

The Board of Directors has determined that none of its directors is "independent" under the criteria set forth in Rule 5065(a)(2) of the Nasdaq Listing Rules. The Board does not have a separately designated audit, nominating, or compensation committee, so the functions normally attributed to these committees are performed by the entire board. Accordingly, none of our directors is "independent" under applicable Nasdaq Listing Rules that define independence for purposes of directors performing the functions of such committees.

**Item 14 - Principal Accountant Fees and Services**

Below is the table of Audit Fees (amounts in US$) billed by our auditors in connection with the audit of the Company's annual financial statements:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Audit Services  | Audit Related Fees | Tax Fees&nbsp;&nbsp;&nbsp;&nbsp;  | &nbsp;&nbsp;&nbsp;&nbsp;Other Fees |
| Year Ended December 31, 2025 | $39750.00 | $27146.25 | $0 | $0 |
| Year Ended December 31, 2024 | $53575.00 | $20858.00 | $0 | $0 |

---

**Item 15 - Exhibits and Financial Statement Schedules**

---

| | |
|:---|:---|
| [31.1](bdpt_ex311.htm) | [Section 302 Certifications under Sarbanes-Oxley Act of 2002](bdpt_ex311.htm) |
| [32.1](bdpt_ex321.htm) | [Section 906 Certification under Sarbanes Oxley Act of 2002](bdpt_ex321.htm) |

---

**Item 16 - Form 10-K Summary**

None

---

| |
|:---|
| 25 |
| *[**Table of Contents**](#TOC)* |

---

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on April 14, 2026.

BioAdaptives, Inc.

---

| |
|:---|
| /s/ James E. Keener |
| James E. Keener |
| Chief Executive Officer |
| (Principal Executive Officer) |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

BioAdaptives, Inc.

---

| |
|:---|
| /s/James E. Keener |
| Chief Financial Officer |
| (Principal Financial Officer) |
| April 14, 2026 |

---

## Exhibit 31.1

**EXHIBIT 31.1**

BioAdaptives Inc.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

I, James E. Keener certify that:

I. I have reviewed this Form 10-K of BioAdaptives Inc.

1. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

2. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

3. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(t) and 15d-15(t)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

4. The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants' ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: April 14, 2026

---

| | |
|:---|:---|
| By:  | /s/ James E Keener |
|  | James E. Keener |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |
|  | BioAdaptives Inc |

---

## Exhibit 31.2

**EXHIBIT 31.2**

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

I, James E Keener, certify that:

1. I have reviewed this Form 10-K of BioAdaptives Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-l5(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and l5d-l5(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Dated: April 14, 2026 | Dated: April 14, 2026 |
| By: | /s/ James E Keener |
|  | James E. Keener |
|  | Chief Financial Officer |
|  | (Principal Financial Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

BioAdaptives Inc.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of BioAdaptives Inc. (the Registrant) on Form 10-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James E Keener, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to James E Keener and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: April 14, 2026

---

| | |
|:---|:---|
| By: | /s/ James E Keener |
|  | James E. Keener |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

## Exhibit 32.2

**EXHIBIT 32.2**

BioAdaptives, Inc

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of BioAdaptives Inc. (the Registrant) on Form I0-K for the period ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the Report), I Robert W. Ellis, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. I350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to James E Keener. and will

be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Dated: April 14, 2026

---

| | |
|:---|:---|
| By: | /s/James E. Keener |
|  | James E. Keener |
|  | Chief Financial Officer |
|  | (Principal Financial Officer) |

---